340 related articles for article (PubMed ID: 30589965)
1. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
2. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
4. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
7. Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Oshima T; Igarashi A; Nakano H; Deguchi H; Fujimori I; Fernandez J
J Clin Gastroenterol; 2022 Jul; 56(6):493-504. PubMed ID: 35470298
[TBL] [Abstract][Full Text] [Related]
8. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
[TBL] [Abstract][Full Text] [Related]
9. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Fass R; Vaezi M; Sharma P; Yadlapati R; Hunt B; Harris T; Smith N; Leifke E; Armstrong D
Aliment Pharmacol Ther; 2023 Nov; 58(10):1016-1027. PubMed ID: 37750406
[TBL] [Abstract][Full Text] [Related]
12. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
13. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
[TBL] [Abstract][Full Text] [Related]
16. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
[TBL] [Abstract][Full Text] [Related]
18. A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
Matsuda S; Kato M; Sakakibara Y; Hamada H; Sasaki Y; Mori H; Hirai Y; Inoue S; Toyokawa T; Kagaya T; Kuwai T; Esaka N; Yamashita H; Watanabe N; Matsumoto M; Fujii H; Demura M; Kubo K; Mabe K; Harada N
J Gastroenterol; 2022 Mar; 57(3):133-143. PubMed ID: 35092498
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Habu Y
Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
[TBL] [Abstract][Full Text] [Related]
20. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Mizokami Y; Oda K; Funao N; Nishimura A; Soen S; Kawai T; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1042-1051. PubMed ID: 28988197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
